Nigeria’s pharmaceutical business has confronted mounting strain from rising manufacturing prices, international change volatility, excessive financing bills and dependence on imported uncooked supplies. For listed drug producers, navigating these challenges whereas defending profitability and sustaining investor confidence has positioned higher duty on their chief monetary officers (CFOs).
Beyond overseeing monetary reporting and regulatory compliance, these executives play important roles in managing liquidity, securing financing, controlling operational prices and supporting growth methods in an more and more aggressive market.
Several pharmaceutical and healthcare companies listed on the Nigerian Exchange (NGX) have recorded important will increase of their market valuations, reflecting altering investor expectations and the monetary efficiency of the sector.
From Fidson Healthcare and MeCure Industries to May & Baker and Neimeth International Pharmaceuticals, the finance executives behind these companies carry expertise spanning funding banking, taxation, company finance and monetary administration.
Nairametrics profiles the finance executives of the largest pharmaceutical and healthcare-related companies listed on the NGX, ranked by market capitalisation as of October 23, 2026.
Osho Olaniyi Thomas — Chief Financial Officer, Juli Plc
Osho Olaniyi Thomas is the Chief Financial Officer of Juli Plc, a Nigerian pharmaceutical and healthcare firm listed on the Nigerian Exchange.
He is liable for the firm’s monetary reporting and accounting oversight, supporting administration in monitoring enterprise efficiency and assembly its monetary disclosure obligations.
Thomas is a Fellow of the Institute of Chartered Accountants of Nigeria and holds a Master of Business Administration diploma, reflecting his skilled background in accounting and enterprise administration.
His place as Chief Financial Officer is documented in Juli Plc’s 2024 audited monetary statements and its monetary stories for the first and second quarters of 2025.
He was amongst the executives who signed the firm’s monetary statements, offering formal accountability for its reported monetary place and efficiency.
Juli Plc operates in the pharmaceutical distribution and healthcare sector, with actions together with the wholesale and retail distribution of pharmaceutical merchandise. Juli Plc recorded a forty five.5% decline in income to N146.86 million in the first half of 2026, in contrast with N269.25 million in H1 2025.
Despite the income decline, the pharmaceutical distributor diminished its web loss by 59.2%, from N31.54 million to N12.86 million, largely by means of value reductions.
The firm’s market capitalisation presently stands at N1.31 billion
Nonye Offorjamah — Head of Finance, Neimeth International Pharmaceuticals Plc
Nonye Offorjamah is the Head of Finance at Neimeth International Pharmaceuticals Plc, with over twenty years of expertise in monetary administration, accounting, taxation and company reporting.
She joined Neimeth in September 2024, following a six-month stint at Simba Group, the place she served as Accounts and Tax Manager.
Before becoming a member of Simba Group, Offorjamah spent practically 18 years at May & Baker Nigeria Plc, holding a number of finance-related positions. Between 2013 and 2024, she served as Subsidiary Operations Accountant and Tax Manager, overseeing monetary reporting, tax compliance and regulatory audits. She beforehand labored as Accounts Payable Manager between 2008 and 2013.
Offorjamah started her skilled profession as a Tax Trainee at KPMG Nigeria in 2001.
She holds a Higher National Diploma in Accountancy from Ondo State Polytechnic, now Rufus Giwa Polytechnic, and has accomplished government coaching at Lagos Business School.
She is a Fellow of the Institute of Chartered Accountants of Nigeria and an Associate Member of the Chartered Institute of Taxation of Nigeria.
Neimeth International Pharmaceuticals Plc recorded a 26% improve in income to N3.66 billion in the first half of 2026, in contrast with N2.91 billion in the corresponding interval of 2025.
According to the firm’s unaudited monetary statements for the six months ended June 30, 2026, revenue after tax elevated marginally by 1.9% to N207.66 million, from N203.76 million in H1 2025.
As of October 23, 2026, Neimeth International Pharmaceuticals Plc had an estimated market capitalisation of N34.67 billion on the NGX
Ayodeji Aboderin — Executive Director/CFO, May & Baker Nigeria Plc
Ayodeji Aboderin is the Executive Director of Finance and Chief Financial Officer of May & Baker Nigeria Plc, a place he has held since January 2014.
With practically three a long time of expertise in monetary administration, budgeting, enterprise technique and company reporting, Aboderin has constructed his profession throughout Nigeria’s manufacturing, meals and beverage, and pharmaceutical industries.
Before becoming a member of May & Baker, he served as Financial Controller at PZ Cussons Nigeria between July 2012 and December 2013. He beforehand spent over 5 years at Dansa Foods Limited, a subsidiary of the Dangote Group, as Head of Management Accounts.
His earlier profession included practically 5 years as a Budget and Finance Analyst at Nigerian Bottling Company, following six years as an Accountant at Standard Flour Mills Limited.
Aboderin holds a Higher National Diploma in Accountancy from The Polytechnic, Ibadan. In 2015, he obtained knowledgeable excellence award from Top Executives publication.
As of October 23, 2026, May & Baker Nigeria Plc had a market capitalisation of roughly N68.58 billion on the Nigerian Exchange. May & Baker Nigeria Plc recorded a 51% improve in revenue earlier than tax to N4.85 billion in the first half of 2026, in contrast with N3.21 billion in the corresponding interval of 2025.
According to the firm’s unaudited monetary statements for the six months ended June 30, 2026, the improved efficiency was pushed primarily by value reductions, stronger working profitability and better curiosity earnings.
Ifedamola Oluwasegun F. — Group Chief Financial Officer, MeCure Group
Ifedamola Oluwasegun F. is the Group Chief Financial Officer of MeCure Group, overseeing the monetary operations of MeCure Industries Plc and MeCure Healthcare Limited.
He assumed the place in December 2021, bringing expertise in funding banking, commerce finance, company technique and capital administration.
Before becoming a member of MeCure, he labored at Platform Capital Investment Partners between 2019 and 2021, rising to Senior Associate in the Investment Banking Group.
He beforehand served as a Trade Finance Officer at Access Bank Plc from 2014 to 2017, the place he dealt with worldwide commerce transactions, credit score services, monetary evaluation and company banking operations.
Earlier in his profession, he labored as a Technical Support Analyst at Capita IT Enterprise Services in the United Kingdom. He additionally co-founded Nokkubo.com, the place he oversaw enterprise technique and monetary planning.
He holds a Master of Science diploma in Finance, Accounting and Management from the University of Bradford and accomplished the Chief Executive Programme at Lagos Business School in 2023.
As of October 23, 2026, MeCure Industries Plc had an estimated market capitalisation of N224.80 billion on the NGX.
MeCure Industries reported a 20.4% improve in income to N44.85 billion in H1 2026, whereas working revenue climbed 41% to N10.90 billion. However, finance prices elevated 54.9% to N5.93 billion
Imokha Ayebae — Finance Director, Fidson Healthcare Plc
Imokha Ayebae is the Finance Director of Fidson Healthcare Plc, with practically twenty years of skilled expertise spanning company finance, monetary advisory, funding banking and administration consulting.
He joined Fidson Healthcare in 2013, initially working in company finance, and has spent over 13 years with the pharmaceutical producer.
Before becoming a member of Fidson, Ayebae labored at FBN Capital Limited between 2009 and 2013, the place he gained expertise in monetary advisory providers.
His earlier profession included a venture administration function at Mouchel in the United Kingdom between 2008 and 2009. He additionally labored in administration consulting at Primecase Consulting from 2007 to 2008.
Ayebae holds a Master of Science diploma in Business Administration, Management and Operations from the University of Warwick, obtained in 2007. He beforehand earned a Bachelor of Engineering diploma in Electronic Systems Engineering from the University of Manchester in 2006.
As of October 23, 2026, Fidson Healthcare Plc had an estimated market capitalisation of N250 billion on the Nigerian Exchange. Fidson Healthcare recorded an 18.9% improve in income to N74.48 billion in H1 2026, whereas revenue after tax rose 28.2% to N7.72 billion. However, commerce receivables surged 139.7% to N26.34 billion, elevating issues about buyer collections and dealing capital regardless of stronger earnings.
Olusola Adeyinka — Chief Financial Officer, Pharma-Deko Plc
Olusola Adeyinka is the Chief Financial Officer of Pharma-Deko Plc, bringing over 25 years of expertise in accounting, auditing, monetary administration and company governance.
He joined Pharma-Deko’s finance staff in 2025, having constructed a profession throughout a number of sectors, together with manufacturing, mining, quarrying, and oil and fuel.
Adeyinka started his skilled profession at Toye Okedara & Co., a agency of chartered accountants in Port Harcourt, the place he accomplished his National Youth Service Corps programme. He was subsequently retained as an Audit Senior, gaining expertise in auditing companies throughout the hospitality, telecommunications and providers industries.
He obtained an accounting qualification from Ogun State Polytechnic, Abeokuta, in 1995, graduating with Upper Credit.
Adeyinka turned an Associate Member of the Institute of Chartered Accountants of Nigeria in May 2009 and was subsequently elevated to Fellow of the institute.
His experience consists of monetary reporting, manufacturing costing, taxation, treasury administration and company monetary technique.
As of October 23, 2026, Pharma-Deko Plc had an estimated market capitalisation of N396.78 million on the NGX.
Other finance executives
Gbenga Oladeinde — Industrial and Medical Gases Nigeria Plc
Gbenga Oladeinde is recognized as the Financial Controller of Industrial and Medical Gases Nigeria Plc. However, Nairametrics couldn’t independently confirm adequate publicly obtainable details about his academic {qualifications}, skilled expertise and profession historical past to arrange an in depth profile.
Olajide Adedayo Abioye — Morison Industries Plc
Olajide Adedayo Abioye is recognized as the Financial Controller of Morison Industries Plc. However, Nairametrics couldn’t independently set up adequate details about his skilled background, academic {qualifications} or earlier appointments to arrange a complete profile.
